• Home
  • The European Society for Medical Oncology Congress 2025

ESMO 2025


Berlin, Germany

The European Society for Medical Oncology Congress 2025
Explore more Oncology congress materials
Material Type

Results(5)

Oncology
A 2-Year Follow-Up of Zanidatamab + mFOLFOX6 ± Bevacizumab in First-Line Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced/Metastatic Colorectal Cancer
Author(s): Sun Young Rha, Keun-Wook Lee, Soohyeon Lee et al.
SAFIR ABC10: Targeted maintenance therapy versus first line standard of care in advanced biliary cancer
Author(s): D. Malka, I. Borbath, A. Lopes et al.
DiscovHER PAN-206: Phase 2 Tumour-Agnostic Study of Zanidatamabin Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Overexpressing Solid Tumours
Author(s): Vivek Subbiah, Vicky Makker, Do-Youn Oh et al.
Clinical Benefit Analysis of a Phase I/II Study Using Lurbinectedin Combined with Ipilimumab and Nivolumab as First-Line Therapy for Advanced Soft Tissue Sarcoma (NCT05876715)
Author(s): Samantha Jeffrey, Anmol Dia Agarwal, Sarosh Syed et al.
Patterns of disease progression and efficacy associated with tumour burden from the Phase 3 IMforte study of lurbinectedin + atezolizumab as first-line maintenance treatment in ES-SCLC
Author(s): Luis Paz-Ares, Hossein Borghaei, Stephen V. Liu et al.